EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Klinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY 4.0

Efficacy and safety of ritlecitinib, an oral JAK3 / TEC family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalis

Natasha Mesinkovska, Brett King iD, Xingqi Zhang, Emma Guttman-Yassky, Nina Magnolo, Rodney Sinclair, Masato Mizuashi iD, Jerry Shapiro, Elena Peeva, Anindita Banerjee, Liza Takiya, Lori Ann Cox und 5 weitere

The Journal of Dermatology · 2024

DOI: 10.1111/1346-8138.17442 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Dermatology, 2024. Verfasst von Natasha Mesinkovska und 16 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, University of California, Irvine, California, USA. Hauptthemen laut MEDLINE: Alopecia, Protein Kinase Inhibitors. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This post‐hoc analysis of the ALLEGRO phase 2b/3 study (NCT03732807) evaluated the efficacy and safety of ritlecitinib, an oral Janus kinase 3/TEC family kinase inhibitor, in patients with alopecia totalis (AT) and alopecia universalis (AU). Patients aged ≥ 12 years with alopecia areata (AA) and ≥50% scalp hair loss received once‐daily ritlecitinib 50 or 30 mg (± 4‐week 200‐mg loading dose) or placebo for 24 weeks. In a subsequent 24‐week extension period, the ritlecitinib groups continued their doses and patients initially assigned to placebo switched to ritlecitinib (200/50 or 50 mg daily). In this analysis, clinician‐ and patient‐reported hair regrowth outcomes were assessed at weeks 24 and 48 in four AA subgroups: AT/AU, AT, AU, and non‐AT/AU. Safety was monitored throughout. Of the 718 randomized patients, 151 (21%) and 147 (20%) were defined as having AT or AU, respectively. At week 24, Severity of Alopecia Tool (SALT) score ≤20 (≤20% scalp hair loss) response rates were higher in the ritlecitinib‐treated AT/AU, AT, and AU groups (7%–14%, 7%–21%, and 4%–10%, respectively) vs the placebo group (0% in the AT/AU, AT, and AU groups). The proportions of patients with a SALT score of ≤20 increased through week 48 (AT/AU, 13%–31%; AT, 11%–27%; AU, 6%–41%). Additionally, at week 24, 25%–43%, 32%–42%, and 12%–50% of patients with AT/AU, AT, and AU, respectively, who received ritlecitinib achieved a moderately or greatly improved response based on the Patient Global Impression of Change scale. Response rates generally increased through week 48 and were similar across AA subgroups. In patients with AT/AU, ritlecitinib was well tolerated with a safety profile consistent with that of the overall AA population. Ritlecitinib demonstrated clinical efficacy, patient‐reported improvement, and an acceptable safety profile in patients with AT and AU through week 48. A plain language summary of this study is available at https://doi.org/10.25454/pfizer.figshare.26879161 . Clinicaltrials.gov : NCT03732807.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AlopeciaProtein Kinase InhibitorsHumansMaleAdultFemaleAdolescentYoung AdultMiddle AgedTreatment OutcomeAdministration, OralDouble-Blind MethodJanus Kinase 3ChildJanus Kinase InhibitorsHairAlopecia AreataBridged-Ring CompoundsPyrimidines

Stichwörter der Autor:innen

ALLEGROJAK3/TECalopecia areataalopecia totalisalopecia universalishair losskinase inhibitorritlectinib

Substanzen

Protein Kinase InhibitorsJanus Kinase 3JAK3 protein, humanJanus Kinase Inhibitors11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,1…Bridged-Ring CompoundsPyrimidines

Autor:innen und Institutionen

  • School of Medicine, University of California, Irvine, California, USA.
  • Yale University School of Medicine, New Haven, Connecticut, USA.
  • The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
  • Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • University Hospital Münster, Münster, Germany.
  • Sinclair Dermatology, Melbourne, Victoria, Australia.

ORCID-Profile: Brett King, Masato Mizuashi

Förderung

  • Pfizer

Zitieren

APA

Mesinkovska, N., King, B., Zhang, X., Guttman-Yassky, E., Magnolo, N., Sinclair, R., Mizuashi, M., Shapiro, J., Peeva, E., Banerjee, A., Takiya, L., Cox, L. A., Wajsbrot, D., Kerkmann, U., Law, E., Wolk, R., & Schaefer, G. (2024). Efficacy and safety of ritlecitinib, an oral JAK3 / TEC family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalis. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.17442

Vancouver

Mesinkovska N, King B, Zhang X, Guttman-Yassky E, Magnolo N, Sinclair R, et al. Efficacy and safety of ritlecitinib, an oral JAK3 / TEC family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalis. The Journal of Dermatology. 2024. doi:10.1111/1346-8138.17442

BibTeX
@article{Mesinkovska2024,
  author = {Mesinkovska, Natasha and King, Brett and Zhang, Xingqi and Guttman-Yassky, Emma and Magnolo, Nina and Sinclair, Rodney and Mizuashi, Masato and Shapiro, Jerry and Peeva, Elena and Banerjee, Anindita and Takiya, Liza and Cox, Lori Ann and Wajsbrot, Dalia and Kerkmann, Urs and Law, Ernest and Wolk, Robert and Schaefer, Gregor},
  title = {Efficacy and safety of ritlecitinib, an oral JAK3 / TEC family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalis},
  journal = {The Journal of Dermatology},
  year = {2024},
  doi = {10.1111/1346-8138.17442}
}
Kostenlos starten →